Navigation Links
Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Date:4/14/2013

TOKYO, April 14, 2013 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503) today announced that Songlin Xue , M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas' Headquarters for the Americas in Northbrook, Illinois, USA and will report to Sef Kurstjens , M.D., Ph.D., newly named Chief Medical Officer at Astellas. In April 2013, Astellas established the Chief Medical Officer position in order to further integrate and enhance Astellas' delivery of global medical solutions.

Astellas President and CEO Yoshihiko Hatanaka said, "I am pleased that Dr. Xue will be joining us at Astellas as head of Global Pharmacovigilance. Dr. Xue's knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities."

With Dr. Xue's appointment, Astellas has now completed the hiring of global heads in the areas of PV, Medical Affairs, Regulatory Affairs, Clinical and Research Quality Assurance, and Quality Assurance.

During his more than twenty years in the pharmaceutical industry, Dr. Xue has held increasingly senior roles with global responsibilities in drug safety and pharmacoepidemiology.  Most recently, Dr. Xue held the position of Senior Vice President, Head Global Pharmacovigilance at Takeda Pharmaceuticals, Inc. Prior to joining Takeda, Dr. Xue held posts with global pharmaceutical companies such as Novartis and Wyeth. 

Dr. Xue received his medical degree from Shanxi Medical College in Shanxi China.  Subsequently, he received a Masters of Science (clinical epidemiology) degree from Hunan University of Medical Science, Hunan, China, and a Doctor of Philosophy degree (Ph.D.) in epidemiology from the University of Minnesota. 

About Astellas Pharma Inc.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and DM Complications and Kidney Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.  


'/>"/>
SOURCE Astellas Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):